Chromatide and Novasep Extends Technology Development Partnership
News May 19, 2008
Chromatide and Novasep have extended their partnership to develop large scale solid phase peptide and oligonucleotide synthesis technology. The resulting systems and equipment will meet the growing needs of biotechnology and pharmaceutical industries for more efficient, continuous flow instruments for gram to industrial scale production of high quality products.
The interest of this partnership is to combine Chromatide's experience in solid phase synthesis of peptide and oligonucleotides, including the production of novel resins and instrumentation, to Novasep' s expertise in synthesis and purification services and technologies in the biotechnology and pharmaceutical industries to provide them with efficient solutions to obtain pure peptides and oligonucleotides.
Commenting on the announcement, Dr Don Wellings, Chromatide's CSO, said, "We are delighted to be continuing to work with Novasep on this project."
He added, "The extension of our collaboration is illustrative of the success we have achieved to date on developing the synthesis systems which Novasep is launching in 2008. Novasep is a world leader in the market with well established relationships within the biotechnology and pharmaceutical sectors which will enable users' rapid access to the technology we are co-developing."
As the world struggles to meet the increasing demand for energy, coupled with the rising levels of CO2 in the atmosphere from deforestation and the use of fossil fuels, photosynthesis in nature simply cannot keep up with the carbon cycle. In a recent paper, researchers report significant progress in optimizing systems that mimic the first stage of photosynthesis, capturing and harnessing light energy from the sun.